Mesenchymal stem cells cause induction of granulocyte differentiation of rat bone marrow C-kit+ hematopoietic stem cells through JAK3/STAT3, ERK, and PI3K signaling pathways

Document Type : Original Article


1 Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran

2 Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

3 Institute of Cell Biology, Medical University of Innsbruck, Biocenter, Innsbruck, Austria

4 Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran


Objective(s): Hematopoietic stem cells (HSCs) are the cells that give rise to different types of blood cells during the hematopoiesis process. Mesenchymal stromal cells (MSCs) as key elements in the bone marrow (BM) niche interact with hematopoietic progenitor cells (HPCs) by secreting cytokines, which control HPCs maintenance and fate. Here we report that BM-MSCs are capable of inducing granulocytic differentiation of the C-Kit+ HSCs via activating JAK3/STAT3, ERK, and PI3K signaling pathways.  
Materials and Methods: For this purpose, BM-MSCs and C-kit+ HSCs were isolated. Next, cells were divided into two groups and differentiated into granulocytes: C-kit+ HSCs alone (control group) and co-cultured C-kit+ HSCs with MSCs (experimental group). Afterward, the gene and protein expression were assessed by real-time PCR and western blotting, respectively.
Results: It was found that BM-MSCs resulted in increased JAK3/STAT3, ERK, and PI3K protein expression in granulocyte differentiated C-kit+ HSCs. 
Conclusion: It should be concluded that MSCs could affect the granulocyte differentiation of C-kit+ HSCs via increasing JAK3/STAT3, ERK, and PI3K signaling pathways.


1. Heidari HR, Fathi E, Montazersaheb S, Mamandi A, Farahzadi R, Zalavi S, et al. Mesenchymal stem cells cause telomere length reduction of molt-4 cells via caspase-3, bad and p53 apoptotic pathway. Int J Mol Cell 2021; 10: 1-10.
2. Hass R, Kasper C, Böhm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal 2011; 9: 1-14.
3. Galán-Díez M, Cuesta-Domínguez Á, Kousteni S. The bone marrow microenvironment in health and myeloid malignancy. Cold Spring Harb Perspect Med 2018; 8: a031328
4. Montazersaheb S, Ehsani A, Fathi E, Farahzadi R, Vietor I. An overview of autophagy in hematopoietic stem cell transplantation. Front Bioeng Biotechnol 2022; 10:849768
5. Wu KH, Wu HP, Chan CK, Hwang SM, Peng CT, Chao YH. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: from bench to bedsides. Cell Transplant 2013; 22: 723-729.
6. Li N, Feugier P, Serrurrier B, Latger-Cannard V, Lesesve JF, Stoltz JF, et al. Human mesenchymal stem cells improve ex vivo expansion of adult human CD34+ peripheral blood progenitor cells and decrease their allostimulatory capacity. Exp Hematol 2007; 35: 507-515.
7. Ito Y, Hasauda H, Kitajima T, Kiyono T. Ex vivo expansion of human cord blood hematopoietic progenitor cells using glutaraldehyde-fixed human bone marrow stromal cells. J Biosci Bioeng 2006; 102: 467-469.
8. da Silva CL, Gonçalves R, Crapnell KB, Cabral JM, Zanjani ED, Almeida-Porada G. A human stromal-based serum-free culture system supports the ex vivo expansion/maintenance of bone marrow and cord blood hematopoietic stem/progenitor cells. Exp Hematol 2005; 33: 828-835.
9. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11: 389-398.
10. Ebrahimi T, Abasi M, Seifar F, Eyvazi S, Hejazi MS, Tarhriz V, et al. Transplantation of stem cells as a potential therapeutic strategy in neurodegenerative disorders. Curr Stem Cell Res  Ther 2020; 16: 133-144.
11.Fathi E, Sanaat Z, Farahzadi R. Mesenchymal stem cells in acute myeloid leukemia: a focus on mechanisms involved and therapeutic concepts. Blood research 2019; 54: 165-174.
12. Fathi E, Valipour B, Farahzadi R. Targeting the proliferation inhibition of chronic myeloid leukemia cells by bone marrow derived-mesenchymal stem cells via erk pathway as a therapeutic strategy. Acta Medica Iranica 2020; 58: 198-206.
13. Fathi E, Vandghanooni S, Montazersaheb S, Farahzadi R. Mesenchymal stem cells promote caspase-3 expression of SHSY5Y neuroblastoma cells via reducing telomerase activity and telomere length. Iran J Basic Med Sci 2021; 24: 1583-1589.
14. Briquet A, Dubois S, Bekaert S, Dolhet M, Beguin Y, Gothot A. Prolonged ex vivo culture of human bone marrow mesenchymal stem cells influences their supportive activity toward NOD/SCID-repopulating cells and committed progenitor cells of B lymphoid and myeloid lineages. Haematologica 2010; 95: 47-56.
15. Chen F, Zhou K, Zhang L, Ma F, Chen D, Cui J, et al. Mesenchymal stem cells induce granulocytic differentiation of acute promyelocytic leukemic cells via IL-6 and MEK/ERK pathways. Stem Cells Dev 2013; 22: 1955-1967.
16. Nikkhah H, Safarzadeh E, Shamsasenjan K, Yousefi M, Lotfinejad P, Talebi M, et al. The effect of bone marrow mesenchymal stem cells on the granulocytic differentiation of HL-60 cells. Turk J Hematol 2018; 35: 42-48.
17. Richter J,Traver D. The role of Wnt signaling in hematopoietic stem cell development. Crit Rev Biochem Mol Biol 2017; 52: 414-424.
18. Miranda M,Johnson D. Signal transduction pathways that contribute to myeloid differentiation. Leukemia 2007; 21: 1363-1377.
19. Montazersaheb S, Fathi E, Farahzadi R. Cytokines and signaling pathways involved in differentiation potential of hematopoietic stem cells towards natural killer cells. Tissue Cell 2021; 70: 101501.
20. Fathi E, Azarbad S, Farahzadi R, Javanmardi S, Vietor I. Effect of rat bone marrow derived-mesenchymal stem cells on granulocyte differentiation of mononuclear cells as preclinical agent in cellbased therapy. Curr Gene Ther 2021; 22: 152-161.
21. Aqmasheh S, Shamsasanjan K, Akbarzadehlaleh P, Pashoutan Sarvar D, Timari H. Effects of mesenchymal stem cell derivatives on hematopoiesis and hematopoietic stem cells. Adv Pharm Bull 2017; 7: 165-177.
22. Adibkia K, Ehsani A, Jodaei A, Fathi E, Farahzadi R, Barzegar-Jalali M. Silver nanoparticles induce the cardiomyogenic differentiation of bone marrow derived mesenchymal stem cells via telomere length extension. Beilstein J Nanotechnol 2021; 12: 786-797.
23. Fathi E,Vietor I. Mesenchymal stem cells promote caspase expression in Molt-4 leukemia cells Via GSK-3α/and ERK1/2 signaling pathways as a therapeutic strategy. Curr Gene Ther 2021; 21: 81-88.
24. Fathi E,Farahzadi R. Mesenchymal stem cells as a cell-based therapeutic strategy targeting the telomerase activity of KG1 acute myeloid leukemia cells. Acta Medica Iranica 2022; 60: 71-77.
25. Czarna A, Sanada F, Matsuda A, Kim J, Signore S, Pereira JD, et al. Single-cell analysis of the fate of c-kit-positive bone marrow cells. NPJ Regen Med 2017; 2: 27-42.
26. Montazersaheb S, Avci ÇB, Bagca BG, Ay NPO, Tarhriz V, Nielsen PE, et al. Targeting TdT gene expression in Molt-4 cells by PNA-octaarginine conjugates. Int J Biol Macromol 2020;164:4583-4590.
27. Bagheri Y, Barati A, Nouraei S, Namini NJ, Bakhshi M, Fathi E, et al. Comparative study of gavage and intraperitoneal administration of gamma-oryzanol in alleviation/attenuation in a rat animal model of renal ischemia/reperfusion-induced injury. Iran J Basic Med Sci 2021; 24: 175-183.
28. Chen J,Pan Y. The safety and clinical efficacy of recombinant human granulocyte colony stimulating factor injection for colon cancer patients undergoing chemotherapy. Rev Assoc Med Bras 2017; 63:1061-1064.
29. Fathi E, Farahzadi R, Valipour B, Sanaat Z. Cytokines secreted from bone marrow derived mesenchymal stem cells promote apoptosis and change cell cycle distribution of K562 cell line as clinical agent in cell transplantation. PLoS One 2019;14: e0215678.
30. Tocci A, Forte L. Mesenchymal stem cell: use and perspectives. Hematol J 2003; 4: 92-96.
31. Kikuchi Y, Kume A, Urabe M, Mizukami H, Suzuki T, Ozaki K, et al. Reciprocal upregulation of Notch signaling molecules in hematopoietic progenitor and mesenchymal stromal cells. J Stem Cells Regen Med 2011; 7: 61-68.
32. Simmons PJ,Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 1991; 78: 55-62.
33. Moreau JE, Chen J, Horan RL, Kaplan DL, Altman GH. Sequential growth factor application in bone marrow stromal cell ligament engineering. Tissue Eng 2005; 11:1887-1897.
34. da Silva CL, Gonçalves R, dos Santos F, Andrade PZ, Almeida-Porada G, Cabral JM. Dynamic cell-cell interactions between cord blood haematopoietic progenitors and the cellular niche are essential for the expansion of CD34+, CD34+CD38- and early lymphoid CD7+ cells. J Tissue Eng Regen Med 2010; 4: 149-158.
35. Mehrasa R, Vaziri H, Oodi A, Khorshidfar M, Nikogoftar M, Golpour M, et al. Mesenchymal stem cells as a feeder layer can prevent apoptosis of expanded hematopoietic stem cells derived from cord blood. Int J Mol Cell Med 2014; 3: 1-10.